NexPlasmaGen has completed an investment phase to accelerate the development of its cold plasma technology for breast cancer treatment
13 Aug 2018
13 Aug 2018
13 Apr 2017
Sophie Lerouge, Professor from the Department of Mechanical Engineering at École de Technologie Supérieure (ETS) and researcher at CRCHUM, and Réjean Lapointe, researcher at CRCHUM, are developing an intelligent biogel to fight cancer.
31 Mar 2017
Following the successful completion of 12 years of research and development between a research team at Université du Québec à Montréal (UQAM) and LUMA Life, the company has recently secured a Class II Medical Device Licence from Health Canada for its lead product, TrimX™.
02 Dec 2016
(job offer available in French)
28 Oct 2016
Last week, Francis Pelletier, President & Renewable Energy Consultant of Arista Energies, was interviewed by Michel Gailloux for Québec Inc., broadcasted by Radio VM. Listen to the complete interview (available in french).
19 Sep 2016
The final of Génies en affaires contest will be held on September 22, from 5 to 8 pm, at the honor hall of Pavillon Roger-Gaudry of the Université de Montréal (2900, boul. Édouard-Montpetit).
07 Sep 2016
La conclusion d’une entente concrétise une collaboration internationale afin de faciliter et accélérer la commercialisation des innovations issues d’universités de Wallonie-Bruxelles et du Québec
18 Jul 2016
Laurent Pharmaceuticals in Biotech Finances (article available in French)
17 Jun 2016
25 Jan 2016
A new injectable “biogel” is effective in delivering anti-cancer agents directly into cancerous tumours and killing them.
25 Nov 2015
05 Nov 2015
Aligo is pleased to highlight the signature of an agreement between Mimetogen and Allergan. MSBi Valorisation, now an integral part of Aligo, helped fuel Mimetogen’s success, through the financing and guidance services provided at the early stage of the company’s development. The benefits generated for MSBi Valorisation, Aligo and McGill University are significant and the results demonstrate the relevance of MSBiV / Aligo business model. We congratulate Mr. Garth Cumberlidge, Mimetogen’s CEO and his team, as well as Dr. Uri Saragovi, the principal researcher whose work led to the discovery of the product developed by Mimetogen, for their accomplishments.
08 Sep 2015
02 Jul 2015
Congratulation to Mr Schubert on his nomination as a member of the Order of Canada!
29 Jun 2015
NoviFlow shines at the Open Network Summit (ONS) 2015
15 Jun 2015
15 Jun 2015
20 May 2015
Beyond the poppy: a new method of opium production…
11 May 2015
MENODYS launches a clinical proof of concept on its innovative Scar Appearance Minimizing Device
09 Mar 2015
French press release follows (No english translation is available)
25 Sep 2014
Mimetogen Pharmaceuticals Inc. (“Mimetogen”) today announced positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles.
OUR PARTNER INSTITUTIONS